Abstract
Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.
Highlights
Opioids are widely used in pain therapy
Intravenous injection of naloxonazine 60 min before buprenorphine administration revealed the same results in all six animals tested
The present study demonstrates that, at an analgesic dose, buprenorphine elicited depression of synaptic strength at spinal C-fibers, which involved the activation of spinal, naloxonazine-sensitive 1-opioid receptors
Summary
Opioids are widely used in pain therapy. Clinically used opioids mainly bind to -opioid receptors, which are expressed throughout the nervous system (Pert and Snyder, 1973). A major part of opioid-induced analgesia depends on a strong, reversible depression of synaptic strength at C-fibers terminating in the superficial spinal dorsal horn (Kohno et al, 1999; Drdla et al, 2009; Heinke et al, 2011). The use of opioids is often limited by the development of side effects such as opioid-induced hyperalgesia (OIH), which is char-. *K.J.G. and R.D.-S. contributed to this work. This article is freely available online through the J Neurosci Author Open Choice option.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.